These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 2309647)

  • 41. Carnitine deficiency induced during hemodialysis and hyperlipidemia: effect of replacement therapy.
    Bertoli M; Battistella PA; Vergani L; Naso A; Gasparotto ML; Romagnoli GF; Angelini C
    Am J Clin Nutr; 1981 Aug; 34(8):1496-500. PubMed ID: 7270472
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Loss of phospholipids asymmetry in red blood cells contributes to anemia in uremic patients.
    Kong QY; Wu X; Li J; Peng WX; Ye R; Lindholm B; Wang T
    Adv Perit Dial; 2001; 17():58-60. PubMed ID: 11510298
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The evaluation of postdialysis L-carnitine administration and its effect on weekly requiring doses of rHuEPO in hemodialysis patients.
    Kadiroglu AK; Yilmaz ME; Sit D; Kara IH; Isikoglu B
    Ren Fail; 2005; 27(4):367-72. PubMed ID: 16060121
    [TBL] [Abstract][Full Text] [Related]  

  • 44. L-carnitine addition to dialysis fluid. A therapeutic alternative for hemodialysis patients.
    Vacha GM; Giorcelli G; d'Iddio S; Valentini G; Bagiella E; Procopio A; di Donato S; Ashbrook D; Corsi M
    Nephron; 1989; 51(2):237-42. PubMed ID: 2915763
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Effect of uremic plasma fractions of different molecular sizes on the filterability of red blood cells].
    Eggert W; Scigalla P; Noack C; Devaux S; Wolf S
    Z Urol Nephrol; 1981 May; 74(5):391-9. PubMed ID: 7269824
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of low dose supplementation of L-carnitine on lipid metabolism in hemodialyzed children.
    Glöggler A; Bulla M; Fürst P
    Kidney Int Suppl; 1989 Nov; 27():S256-8. PubMed ID: 2636667
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Carnitine and lipid profile in uremia.
    Savica V; Bellinghieri G
    Clin Ter; 1997; 148(5-6):229-36. PubMed ID: 9377858
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [The influence of renal failure and renal replacement therapy on the activity of erythrocyte sodium-proton exchanger].
    Kwiatkowska E
    Ann Acad Med Stetin; 2004; 50(1):25-33. PubMed ID: 16871741
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Studies on the factors responsible for low erythrocyte alpha-tocopherol concentrations in patients on maintenance hemodialysis].
    Mori K
    Nihon Jinzo Gakkai Shi; 1989 Mar; 31(3):309-19. PubMed ID: 2739127
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Hemodialysis does not influence the peroxidative state already present in uremia.
    Hirayama A; Nagase S; Gotoh M; Takemura K; Tomida C; Ueda A; Aoyagi K; Terao J; Koyama A
    Nephron; 2000 Dec; 86(4):436-40. PubMed ID: 11124591
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Whole body fat oxidation before and after carnitine supplementation in uremic patients on chronic haemodialysis.
    Lundholm K; Persson H; Wennberg A
    Clin Physiol; 1988 Aug; 8(4):417-26. PubMed ID: 3409653
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Carnitine action on red blood cell osmotic resistance in hemodialysis patients.
    Vlassopoulos DA; Hadjiyannakos DK; Anogiatis AG; Evageliou AE; Santikou AV; Noussias CV; Papandreou PT; Hadjiconstantinou VE
    J Nephrol; 2002; 15(1):68-73. PubMed ID: 11936429
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Toward personalized hemodialysis by low molecular weight amino-containing compounds: future perspective of patient metabolic fingerprint.
    Sirolli V; Rossi C; Di Castelnuovo A; Felaco P; Amoroso L; Zucchelli M; Ciavardelli D; Di Ilio C; Sacchetta P; Bernardini S; Arduini A; Bonomini M; Urbani A
    Blood Transfus; 2012 May; 10 Suppl 2(Suppl 2):s78-88. PubMed ID: 22890273
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Secondary L-carnitine deficiency in chronic hemodialysis patients].
    Achenbach H; Würzberger G; Seim H; Löster H; Strauss B
    Z Gesamte Inn Med; 1989 Jan; 44(1):18-22. PubMed ID: 2711712
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Low dose of L-carnitine impairs membrane fragility of erythrocytes in hemodialysis patients.
    Bérard E; Barrillon D; Iordache A; Bayle J; Cassuto-Viguier E
    Nephron; 1994; 68(1):145. PubMed ID: 7991030
    [No Abstract]   [Full Text] [Related]  

  • 56. Lipid-lowering effect of carnitine in chronically uremic patients treated with maintenance hemodialysis.
    Guarnieri GF; Ranieri F; Toigo G; Vasile A; Ciman M; Rizzoli V; Moracchiello M; Campanacci L
    Am J Clin Nutr; 1980 Jul; 33(7):1489-92. PubMed ID: 7395772
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Phosphate in dialysis patients.
    Sugisaki H; Onohara M; Kunitomo T
    Trans Am Soc Artif Intern Organs; 1983; 29():38-43. PubMed ID: 6673257
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Relation between echinocytosis and erythrocyte calcium content in hemodialyzed uremic patients.
    Agroyannis B; Kopelias I; Fourtounas C; Paraskevopoulos A; Tzanatos H; Dalamangas A; Mallas E
    Artif Organs; 2001 Jun; 25(6):486-90. PubMed ID: 11453880
    [TBL] [Abstract][Full Text] [Related]  

  • 59. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of L-carnitine administration on erythropoietin use in thalassemic minor haemodialysis patients.
    Di Iorio BR; Guastaferro P; Cillo N; Cucciniello E; Bellizzi V
    Nephrol Dial Transplant; 2007 Mar; 22(3):954-5; author reply 955-6. PubMed ID: 17132710
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.